Basis: FMP quote market capitalization / book value attributable to common shareholders (matching reported total stockholders equity minus preferred stock). Source: stored company filings and market data; unavailable inputs remain N/A.
The P/B ratio is N/A as of 2026-10-06T18:03:28.400Z.
Calculation as of: 2026-10-06T18:03:28.400Z.
Quote observation: 2026-10-06T18:00:21.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PB RATIO
N/A
Market Cap
$982.42M
PB Ratio
2.89
TTM Avg
4.05
3Y Avg
8.50
5Y Avg
7.94
Market Cap
$982.34M
PB Ratio
2.96
TTM Avg
2.29
3Y Avg
2.27
5Y Avg
2.27
Market Cap
$1.02B
PB Ratio
1.65
TTM Avg
1.66
3Y Avg
1.66
5Y Avg
1.66
| NAME | MARKET CAP | PB RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Latigo Biotherapeutics Inc. (LTGO) | $990.42M | N/A | N/A | N/A | N/A |
| MeiraGTx Holdings plc (MGTX)vs › | $984.44M | 4.57 | 106.69 | 30.01 | 17.30 |
| PROCEPT BioRobotics Corporation (PRCT)vs › | $982.42M | 2.89 | 4.05 | 8.50 | 7.94 |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $982.34M | 2.96 | 2.29 | 2.27 | 2.27 |
| Vor Biopharma Inc. (VOR)vs › | $997.50M | N/A | 1.14 | 1.01 | 1.17 |
| Pacira BioSciences, Inc. (PCRX)vs › | $973.18M | 1.45 | 1.46 | 1.48 | 2.18 |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $1.01B | 3.13 | 2.19 | 1.54 | 1.38 |
| Aktis Oncology, Inc. (AKTS)vs › | $966.09M | 1.99 | 2.48 | 2.48 | 2.48 |
| Lumexa Imaging Holdings, Inc. Common Stock (LMRI)vs › | $1.02B | 1.65 | 1.66 | 1.66 | 1.66 |
| Janux Therapeutics, Inc. (JANX)vs › | $1.03B | 1.11 | 1.11 | 2.25 | 2.05 |
P/B Ratio
N/A
Market Price / Book Value per Share
PB Ratio = Market Cap / (Total Shareholders' Equity − Preferred Stock)
The price-to-book ratio compares market capitalization to book value attributable to common shareholders (total equity minus preferred stock). Lower values can indicate a cheaper valuation relative to net assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
